You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

Mary's Medicinals to participate in CMS trial programme with cannabinoid-based wellness products

Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development

Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal

Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management

GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure

Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences

GXO appointed to manage NHS England bowel cancer home testing kits

Hoth Therapeutics deploys OpenClaw AI platform for drug discovery

Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator

Iterion Therapeutics reports first patient dosed in phase 1/2 trial of tegavivint in colorectal cancer

SciTech Development reports early-stage clinical data from Phase 1a trial of ST-001 nanoFenretinide at USCLC Annual Workshop 2026

Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics

Merck to acquire Terns Pharmaceuticals for USD6.7bn

Myosin Therapeutics granted USD2m funding from Florida Department of Health

Akeso's Phase II trials of AK146D1 and AK138D1 approved in China

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026